Watch BNGO. Know when insiders buy.
One email the day a filing lands. Free.
Work order
43
WATCH · insiders 55, shorts 31
Insiders, 90 days
+$5K
net buying · 1 buy, 0 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $14.1MP/E —DIV YIELD —FCF YIELD —REV TTM $30.2M +10.0%NET INCOME −$32.2MNET DEBT $11.1M52W 1.06 – 4.92NEXT EARNINGS Nov 12SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $8.2M | +21.4% | 52.8% | −$7.2M | −$7.4M | — | -0.64 | −$4.7M | — | — | Aug 10 |
| Q1 2026 · Mar 31 | $6.7M | +3.6% | 48.6% | −$7.9M | −$8.3M | — | -0.76 | −$5.7M | — | — | Aug 10 |
| Q4 2025 · Dec 31derived | $8M | −2.6% | 42.7% | −$8.5M | −$7.9M | — | -0.03 | −$4.2M | — | — | Mar 23 |
| Q3 2025 · Sep 30 | $7.4M | +21.3% | 45.7% | −$8.5M | −$8.5M | — | -1.59 | −$5.9M | — | — | Nov 13 |
| Q2 2025 · Jun 30 | $6.7M | −13.4% | 51.6% | −$7.8M | −$6.9M | — | -1.99 | −$3.5M | — | — | Aug 10 |
| Q1 2025 · Mar 31 | $6.5M | −26.4% | 45.5% | −$8.5M | −$3.1M | — | -1.15 | −$2.8M | — | — | Aug 10 |
| Q4 2024 · Dec 31derived | $8.2M | −23.9% | 41.9% | −$11.9M | −$20.1M | — | -7.95 | −$6.5M | — | — | Mar 23 |
| Q3 2024 · Sep 30 | $6.1M | −34.8% | -139.1% | −$43.9M | −$44.2M | — | -30.92 | −$13.3M | — | — | Nov 13 |
| Q2 2024 · Jun 30 | $7.8M | — | 33.3% | −$17M | −$16.2M | — | -14.41 | −$21M | — | — | Nov 13 |
| Q1 2024 · Mar 31 | $8.8M | — | 32.2% | −$31.1M | −$31.4M | — | -35.75 | −$28.1M | — | — | Nov 13 |
| Q4 2023 · Dec 31derived | $10.7M | — | 22.7% | −$25M | −$43.9M | — | -402.75 | −$29.8M | — | — | Mar 31 |
| Q3 2023 · Sep 30 | $9.3M | — | 29.5% | −$113.2M | −$112.6M | — | -3.22 | −$26.3M | — | — | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $28.5M | 46.3% | −$33.3M | −$26.4M | -92.6% | -4.85 | −$16.3M | — | — | — | — |
| FY2024 · to Dec 31 | $30.8M | 1.2% | −$104M | −$112M | -364.0% | -88.13 | −$68.9M | — | — | — | — |
| FY2023 · to Dec 31 | $36.1M | 26.5% | −$215.2M | −$232.5M | -643.7% | -408.60 | −$125.2M | — | — | — | — |
| FY2022 · to Dec 31 | $27.8M | 21.4% | −$131.7M | −$132.6M | -476.9% | -4.58 | −$124.8M | — | — | — | — |
| FY2021 · to Dec 31 | $18M | 21.5% | −$77.1M | −$72.4M | -402.8% | -0.26 | −$71.9M | — | — | — | — |
| FY2020 · to Dec 31 | $8.5M | 32.6% | −$38.6M | −$41.1M | -483.4% | -0.39 | −$38.3M | $0 | −$38.3M | — | — |
Every number comes from Bionano Genomics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.